We found that H1A treatment resulted in significantly higher frequencies of MHC-II high CD80 + monocytes (defined by TCRβ − CD11b + Ly6C + F4/80 − cells), compared with ATZ, and trending towards significance, compared with PBS ( figure 2B ).
← all excerpts
Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion.
1
—
—